Charles Homcy - Global Blood Director
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
Director
Dr. Charles J. Homcy, M.D. is no longer Independent Director of Global Blood Therapeutics Inc., effective June 18, 2019. Dr. Homcy joined Third Rock Ventures, a VC firm, where he is now a partner. He served as president and chief executive officer of Portola Pharmaceuticals, Inc., a biopharmaceutical company, since cofounding the company in 2003 until 2010. Prior to that, Dr. Homcy served as the president of research and development at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, following its acquisition of COR Therapeutics Inc. in 2002. He joined COR in 1995 as executive vice president of research and development, and he served as a director of the company from 1998 to 2002. Dr. Homcy was a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital since 1997. He was previously president of the medical research division of American CyanamidLederle Laboratories, a division of WyethAyerst Laboratories. He currently serves on the board of directors of Portola and Pliant Therapeutics, Inc. Dr. Homcy holds a B.A. and an M.D. from Johns Hopkins University. Dr. Homcy is a member of the board of trustees of Johns Hopkins University. Dr. Homcys qualifications to serve on our Board of Directors include his significant experience building and leading successful biotechnology companies and his scientific expertise. since 2017.
| Age | 68 |
| Tenure | 7 years |
| Phone | 650 741-7700 |
| Web | www.globalbloodtx.com |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brian Greenspun | Barrick Gold Corp | 73 | |
| Robert Bohn | Parker Hannifin | 66 | |
| Jillian Evanko | Parker Hannifin | 42 | |
| Max Sisulu | Harmony Gold Mining | 73 | |
| Norborne Cole | Barrick Gold Corp | 73 | |
| Given Sibiya | Harmony Gold Mining | 52 | |
| Laura Thompson | Parker Hannifin | 56 | |
| Simo Lushaba | Harmony Gold Mining | 54 | |
| Joseph Scaminace | Parker Hannifin | 67 | |
| Jeanine Lioko | Barrick Gold Corp | 52 | |
| Jonathan Rubenstein | Eldorado Gold Corp | 67 | |
| Safiatou BaNDaw | Barrick Gold Corp | 64 | |
| Brett Harvey | Barrick Gold Corp | 67 | |
| John Wetton | Harmony Gold Mining | 71 | |
| KlausPeter Mueller | Parker Hannifin | 74 | |
| Michael Price | Eldorado Gold Corp | 63 | |
| Candy Obourn | Parker Hannifin | 69 | |
| James Burns | One Liberty Properties | 74 | |
| Joseph Amato | One Liberty Properties | 78 | |
| Grathel Motau | Harmony Gold Mining | 45 | |
| John Webster | Eldorado Gold Corp | 65 | |
Management Performance
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
| Michael Bonney, Director | ||
| Stephanie Yao, IR Contact Officer | ||
| Myesha Lacy, IR Contact Officer | ||
| Mark Perry, Independent Director | ||
| Jeffrey Farrow, CFO | ||
| Myesha Edwards, IR Contact Officer | ||
| Philip Pizzo, Director | ||
| Glenn Pierce, Director | ||
| Willie Brown, Independent Director | ||
| Wendy Yarno, Director | ||
| Kevin Starr, Director | ||
| Hing Sham, Senior Vice President - Chemistry | ||
| Scott Morrison, Director | ||
| Deval Patrick, Independent Director | ||
| Tricia Suvari, Chief Legal Officer | ||
| Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
| David Johnson, Chief Commercial Officer | ||
| Charles Homcy, Director | ||
| Dawn Svoronos, Director | ||
| Ted Love, President CEO, Director | ||
| Eleanor Ramos, Chief Medical Officer | ||
| John Schembri, Vice President of Finance and Administration | ||
| Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Global Blood in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Global Blood's short interest history, or implied volatility extrapolated from Global Blood options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |